Chemoproteomics reveals baicalin activates hepatic CPT1 to ameliorate diet-induced obesity and hepatic steatosis

Obesity and related metabolic diseases are becoming worldwide epidemics that lead to increased death rates and heavy health care costs. Effective treatment options have not been found yet. Here, based on the observation that baicalin, a flavonoid from the herbal medicine Scutellaria baicalensis, has...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 115; no. 26; pp. E5896 - E5905
Main Authors Dai, Jianye, Liang, Kai, Zhao, Shan, Jia, Wentong, Liu, Yuan, Wu, Hongkun, Lv, Jia, Cao, Chen, Chen, Tao, Zhuang, Shentian, Hou, Xiaomeng, Zhou, Shijie, Zhang, Xiannian, Chen, Xiao-Wei, 陈晓伟, Huang, Yanyi, Xiao, Rui-Ping, Wang, Yan-Ling, Luo, Tuoping, Xiao, Junyu, Wang, Chu
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 26.06.2018
SeriesPNAS Plus
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Obesity and related metabolic diseases are becoming worldwide epidemics that lead to increased death rates and heavy health care costs. Effective treatment options have not been found yet. Here, based on the observation that baicalin, a flavonoid from the herbal medicine Scutellaria baicalensis, has unique antisteatosis activity, we performed quantitative chemoproteomic profiling and identified carnitine palmitoyltransferase 1 (CPT1), the controlling enzyme for fatty acid oxidation, as the key target of baicalin. The flavonoid directly activated hepatic CPT1 with isoform selectivity to accelerate the lipid influx into mitochondria for oxidation. Chronic treatment of baicalin ameliorated diet-induced obesity (DIO) and hepatic steatosis and led to systemic improvement of other metabolic disorders. Disruption of the predicted binding site of baicalin on CPT1 completely abolished the beneficial effect of the flavonoid. Our discovery of baicalin as an allosteric CPT1 activator opens new opportunities for pharmacological treatment of DIO and associated sequelae.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Author contributions: J.D. and C.W. designed research; J.D., K.L., S. Zhao, W.J., Y.L., H.W., J.L., C.C., T.C., S. Zhuang, X.H., and S. Zhou performed research; X.-W.C., Y.H., R.-P.X., Y.-L.W., T.L., and J.X. contributed new reagents/analytic tools; J.D., X.Z., and C.W. analyzed data; and J.D. and C.W. wrote the paper.
Edited by Benjamin F. Cravatt, The Scripps Research Institute, La Jolla, CA, and approved May 15, 2018 (received for review January 30, 2018)
ISSN:0027-8424
1091-6490
1091-6490
DOI:10.1073/pnas.1801745115